Systemic antifungal agents

Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print

Volumn , Issue , 2012, Pages 98-120

  Gupta, Aditya K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944529663     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2003-7.00009-1     Document Type: Chapter

References (133)

1. Sporonox (itraconazole) Capsules prescribing information November 2009, Janssen Pharmaceuticals Inc.
2. Sporonox (itraconazole) Oral Solution prescribing information April 2011, Centocor Ortho Biotech Products, L.P.
3. Sporonox (itraconazole capsules) Product Monograph March 2011, Janssen Inc (Canada).
4. Diflucan (fluconazole tablets) (fluconazole injection-for intravenous infusion only) (fluconazole for oral suspension) prescribing information June 2011, Pfizer.
5. Lamisil (terbinafine hydrochloride) Tablets prescribing information March 2011, Novartis Pharmaceuticals Corporation.
6. Lamisil (terbinafine hydrochloride) Oral Granules prescribing information March 2011, Novartis Pharmaceuticals Corporation.
7. Lin C-C, Magat J, Chang R, et al. Absorption, metabolism and excretion of 14C-griseofulvin in man. J Pharmacol Exp Ther 1973, 187(2):415-422.
8. Schafer-Korting M, Korting HC, Mutschler E Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Eur J Clin Pharmacol 1985, 29:109-113.
9. Gris-PEG (griseofulvin ultramicrosize) Tablets prescribing information October 2010, Pedinol Pharmacal Inc.
10. VFEND (voriconazole) Tablets, Oral Suspension and I.V. prescribing information June 2011, Pfizer.
11. Noxafil (posaconazole) Oral Suspension prescribing information September 2010, Merck & Co, Inc.
12. Posanol (posaconazole) Oral Suspension prescribing information February 2011, Merck Canada, Inc.
13. Faergemann J, Zehender H, Jones T, et al. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum, and eccrine sweat. Acta Derm Venereol 1990, 71:322-326.
14. Lever LR, Dykes PJ, Thomas R, et al. How orally administered terbinafine reaches the stratum corneum. J Dermatol Treat 1990, 1:23-25.
15. Faergemann J, Zehender H, Denouël J, et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993, 73:305-309.
16. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988, 18:263-268.
17. Grant SM, Clissold SP Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989, 37:310-344.
18. De Doncker P Pharmacokinetics of oral antifungal agents. Dermatol Ther 1997, 3:46-57.
19. Piérard G, Arrese J, De Doncker P Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995, 32:429-435.
20. Faergemann J, Laufen H Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993, 18:102-106.
21. Wildfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994, 37:127-130.
22. Schatz F, Bräutigam M, Dobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995, 20:377-383.
23. Faergemann J, Zehender H, Millerioux L Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994, 19:121-126.
24. De Doncker P, Decroix J, Piérard GE, et al. Itraconazole pulse therapy is effective in the treatment of onychomycosis: a pharmacokinetic/pharmacodynamic and clinical evaluation. Arch Dermatol 1996, 132:34-41.
25. Willemsen M, De Doncker P, Willems J, et al. Post-treatment itraconazole levels in the nail. New implications for treatment in onychomycosis. J Am Acad Dermatol 1992, 26:731-735.
26. Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis: an overview. Int J Dermatol 1998, 37:303-308.
27. Hay RJ Pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1992, 1(Suppl 2):6-7.
28. Faergemann J, Laufen H Levels of fluconazole in normal and diseased nails during and after treatment of onychomycosis in toe-nails with fluconazole 150 mg once weekly. Acta Derm-Venereol 1996, 76:219-221.
29. Baudraz-Rosselet F, Monod M, Jaccoud S, et al. Efficacy of terbinafine treatment of tinea capitis in children varies according to the dermatophyte species. Br J Dermatol 1996, 135:1011-1012.
30. Dragoš V, Lunder M Lack of efficacy of 6-week treatment with oral terbinafine for tinea capitis due to Microsporum canis in children. Pediatr Dermatol 1997, 14:46-48.
31. Gupta AK, Hofstader SLR, Adam P, et al. Tinea capitis: an overview with an emphasis on management. Pediatr Dermatol 1999, 16:171-189.
32. Gupta AK, Groen K, Woestenborghs R, et al. Itraconazole is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis. Clin Exp Dermatol 1998, 23:103-108.
33. Ryder NS Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992, 126:2-7.
34. Haria M, Bryson HM, Goa KL Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996, 51:585-620.
35. Grant SM, Clissold SP Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990, 39:877-917.
36. Gupta AK, Kohli Y, Batra R In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med Mycol 2005, 43:179-185.
37. Carrillo-Muñoz AJ, Giusiano G, Guarro J, et al. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int J Antimicrobial Agents 2007, 30:157-161.
38. Bueno JG, Martinez C, Zapata B, et al. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clin Exp Dermatol 2010, 35:658-663.
39. Nandedkar-Thomas MA, Scher RK An update on disorders of the nails. J Am Acad Dermatol 2005, 52:877-887.
40. Gupta AK, Cooper EA, Ryder JE, et al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 2004, 5:225-237.
41. Olafsson JH, Sigurgeirsson B, Baran R Combination therapy for onychomycosis. Br J Dermatol 2003, 149(Suppl 65):15-18.
42. Evans EGV Drug synergies and the potential for combination therapy in onychomycosis. Br J Dermatol 2003, 149(Suppl 65):11-13.
43. Gupta AK Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 2005, 4:481-485. Onychomycosis Combination Therapy Study Group.
44. Baran R, Hay RJ, Garduno JI Review of antifungal therapy, part II: Treatment rationale, including specific patient populations. J Dermatolog Treat 2008, 19(3):168-175.
45. Gupta AK, Ryder JE The use of oral antifungal agents to treat onychomycosis. Dermatol Clin 2003, 21:469-479.
46. Gupta AK, Ryder JE, Johnson AM Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004, 150:537-544.
47. Taush I, Bräutigam M, Weidinger G, et al. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. Br J Dermatol 1997, 136:737-742.
48. van der Schroeff JG, Cirkel PKS, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992, 126:36-39.
49. Gianni C The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 2009, 23:256-262.
50. Odom RB, Aly R, Scher R, et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol 1997, 36:231-235.
51. Wu J, Wen H, Liao W Small-dose itraconazole pulse therapy in the treatment of onychomycosis. Mycoses 1997, 40:397-400.
52. Brown SJ Efficacy of fluconazole for the treatment of onychomycosis. Ann Pharmacother 2009, 43:1684-1691.
53. Tosti A, Piraccini BM, Lorenzi S, et al. Treatment of nondermatophyte mold and Candida onychomycosis. Dermatol Clin 2003, 21:491-497.
54. Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology and treatment. J Am Acad Dermatol 2011, ) (epublished only, as at November.
55. Gupta AK, Gregurek-Novak T Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 2001, 202:235-238.
56. Nolting S, Bräutigam M, Weidinger G Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994, 30(Suppl 43):16-21.
57. Roberts DT, Richardson MD, Dwyer PK, et al. Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992, 2(Suppl 1):39-42.
58. Segal R, Kitzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996, 35:958-961.
59. Kim JA, Ahn KJ, Kim JM, et al. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study. Curr Ther Res 1995, 56:1066-1075.
60. Tosti A, Piraccini DM, Vincenzi C, et al. Itraconazole in the treatment of two young brothers with chronic mucocutaneous candidiasis. Pediatr Dermatol 1997, 14:146-148.
61. Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988, 119:359-366.
62. Gupta AK, Summerbell RC Tinea capitis. Med Mycol 2000, 38:255-287.
63. Roberts BJ, Friedlander SF Tinea capitis: a treatment update. Pediatric Annals 2005, 34:191-200.
64. Tey HL, Tan AS, Chan YC Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J Am Acad Dermatol 2011, 64(4):663-670.
65. Elewski BE, Caceres HW, DeLeon L, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: Results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol 2008, 59(1):41-54.
66. Ginter-Hanselmayer G, Seebacker C Treatment of tinea capitis - a critical appraisal. J Dtsch Dermatol Ges 2011, 9:109-114.
67. Chan Y, Friedlander SF New treatments for tinea capitis. Curr Opin Infect Dis 2004, 17:97-103.
68. Haroon TS, Hussain I, Aman S, et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 1996, 135:86-88.
69. Friedlander SF, Aly R, Krafchik B, et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics 2002, 109:602-607.
70. Lipozencic J, Skerlev M, Orofino-Costa R, et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol 2002, 146:816-823.
71. Gupta AK, Solomon RS, Adam P Itraconazole oral solution for the treatment of tinea capitis. Br J Dermatol 1998, 139:104-106.
72. Dastghaib L, Azizzadeh M, Jafari P Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. J Dermatolog Treat 2005, 16:43-46.
73. Montero Gei F Fluconazole in the treatment of tinea capitis. Int J Dermatol 1998, 37:870-871.
74. Gupta AK, Dlova N, Taborda P, et al. Once weekly fluconazole is effective in the treatment of tinea capitis: a prospective, multicentre study. Br J Dermatol 2000, 142:965-968.
75. Gupta AK, Chaudhry M, Elewski B Tinea corporis, tinea cruris, tinea nigra and piedra. Dermatol Clin 2003, 21:395-400.
76. Gupta AK, Chow M, Daniel CR Treatments of tinea pedis. Dermatol Clin 2003, 21:431-462.
77. De Doncker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997, 37:969-974.
78. Parent D, Decroix J, Heenen M Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology 1994, 189:378-381.
79. Gupta AK, De Doncker P, Heremans A, et al. Itraconazole for the treatment of tinea pedis: a dose of 400 mg daily given for 1 week is similar in efficacy to 100 or 200 mg daily given for 2 to 4 weeks. J Am Acad Dermatol 1997, 36:789-792.
80. Stary A, Sarnow E Fluconazole in the treatment of tinea corporis and tinea cruris. Dermatology 1998, 196:237-241.
81. Kotogyan A, Harmanyeri Y, Tahsin Gunes A, et al. Efficacy and safety of oral fluconazole in the treatment of patients with tinea corporis, cruris or pedis or cutaneous candidiasis. A multicentre, open, non-comparative study. Clin Drug Invest 1996, 12:59-66.
82. Gomez M, Arenas R, Salazar JJ, et al. Tinea pedis. A multicentre trial to evaluate the efficacy and tolerance of a weekly dose of fluconazole. Dermatologia Rev Mex 1996, 40:251-255.
83. Del Aguila R, Montero Gei F, Robles M, et al. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea pedis. Clin Exp Dermatol 1992, 17:402-406.
84. Ketoconazole Tablets USP, 200 mg Prescribing Information April 1998, Teva Pharmaceuticals.
85. Gupta AK, Batra R, Bluhm R, et al. Pityriasis versicolor. Dermatol Clin 2003, 21:413-429.
86. Gupta AK, Kogan N, Batra R Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother 2005, 6:165-178.
87. Gupta AK, Ryder JE, Nicol K, et al. Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. Clin Dermatol 2003, 21:417-425.
88. Hu SW, Bigby M Pityriasis versicolor: A systemic review of interventions. Arch Dermatol 2010, 146:1132-1140.
89. Zaias N Pityriasis versicolor with ketoconazole. J Am Acad Dermatol 1989, 20(4):703-705.
90. Rausch LJ, Jacobs PH Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 1984, 34:470-471.
91. Gupta AK, Bluhm R, Cooper EA, et al. Seborrheic dermatitis. Dermatol Clin 2003, 21:401-412.
92. Stefanaki I, Katsambas A Therapeutic update on seborrheic dermatitis. Skin Therapy Lett 2010, 15:1-4.
93. Gupta AK, Cooper EA, Montero-Gei F The use of fluconazole to treat superficial fungal infections in children. Dermatol Clin 2003, 21:537-542.
94. Gupta AK, Cooper EA, Ginter G Efficacy and safety of itraconazole use in children. Dermatol Clin 2003, 21:521-535.
95. Gupta AK, Cooper EA, Lynde CW The efficacy and safety of terbinafine in children. Dermatol Clin 2003, 21:511-520.
96. Gupta AK, Skinner AR Onychomycosis in children: a brief overview with treatment strategies. Pediatr Dermatol 2004, 21:74-79.
97. Tosti A, Piraccini BM, Iorizzo M Management of onychomycosis in children. Dermatol Clin 2003, 21:507-509.
98. Gupta AK, Sibbald RG, Lynde CW, et al. The prevalence of onychomycosis in children and treatment strategies. J Am Acad Dermatol 1997, 36:395-402.
99. Gupta AK, Chang P, Del Rosso JQ, et al. Onychomycosis in children: prevalence and management. Pediatr Dermatol 1998, 15:464-471.
100. Jones TC Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol 1995, 132:683-689.
101. Gupta AK, Del Rosso JQ Management of onychomycosis in children. Postgrad Med J 1999, Suppl 38:29-35.
102. Goulden V, Goodfield MJD Treatment of childhood dermatophyte infections with oral terbinafine. Pediatr Dermatol 1995, 12:53-54.
103. Gupta AK, Adam P, Hofstader SLR Itraconazole oral solution for the treatment of onychomycosis. Pediatr Dermatol 1998, 15:472-474.
104. Hay RJ Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol 1999, 141(Suppl 56):36-40.
105. Meis JFGM, Verweij PE Current management of fungal infections. Drugs 2001, 61(Suppl 1):13-25.
106. Herbrecht R, Nivoix Y, Fohrer C, et al. Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother 2005, 56(Suppl. S1):i39-i48.
107. Freifeld AG, Bariola JR, Andes D The role of second-generation antifungal triazoles for treatment of the endemic mycoses. Curr Infect Dis Rep 2010, 12:471-478.
108. Gupta AK, Prussick R, Sibbald RG, et al. Terbinafine in the treatment of Majocchi's granuloma. Int J Dermatol 1995, 34:489.
109. Wingfield A, Fernandez-Obregon A, Wignall A, et al. Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole. Br J Dermatol 2004, 150:119-126.
110. Bonifaz A, Vázquez-González D Tinea imbricata in the Americas. Curr Opin Infect Dis 2011, 24:106-111.
111. Francesconi G, Francesconi do Valle AC, Passos SL, et al. Comparative study of 250 mg daily terbinafine and 100 mg daily itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia 2011, 171(5):349-354.
112. Gip L Black piedra: the first case treated with terbinafine (Lamisil). Br J Dermatol 1994, 130:26-28.
113. Schiraldi GF, Circero SL, Colombo MD, et al. Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Br J Dermatol 1996, 134(Suppl 46):25-29.
114. Esterre P, Inzan CK, Ratsioharana M, et al. A multicenter trial of terbinafine in patients with chromoblastomycosis: effect on clinical and biological criteria. J Dermatolog Treat 1998, 9(Suppl 1):S29-S34.
115. Berger TG, Heon V, King C, et al. Itraconazole therapy for human immunodeficiency virus-associated eosinophilic folliculitis. Arch Dermatol 1995, 31:358-360.
116. Burke WA Use of itraconazole in a patient with chronic mucocutaneous candidiasis. J Am Acad Dermatol 1989, 21:1309-1310.
117. Stengel F, Robbo-Soto N, Galinberti R, et al. Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. Int J Dermatol 1994, 33:726-729.
118. Effendy I, Krause W In vivo effects of terbinafine and ketoconazole on tstosterone plasma levels in healthy males. Dermatologica 1989, 178(2):103-106.
119. Queiroz-Telles F, Purim KS, Boguswewski CL, et al. Adrenal response to corticotrophin and testosterone during long-terme therapy with itraconazole in patients with chromoblastomycosis. J Antimicrob Chemother 1997, 40(6):899-902.
120. Hanger DP, Jevons S, Shaw JTB Fluconazole and testosterone: In vivo and in vitro studies. Antimicrob Agents Chemother 1988, 32:646-648.
121. Gupta AK, Ryder JE, Lynch LE, et al. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. J Drugs Dermatol 2005, 4:302-308.
122. Gupta AK, Lynde CW, Lauzon GJ, et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol 1998, 138:529-532.
123. Wolf R, Orion E, Marcos B, et al. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 2005, 23:171-181.
124. Hay RJ Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993, 29:S50-S54.
125. Orion E, Matz H, Wolf R The life-threatening complications of dermatologic therapies. Clin Dermatol 2005, 23:182-192.
126. Nashan D, Knuth UA, Weidinger G, et al. The antimycotic drug terbinafine in contrast to ketoconazole lacks acute effects on the pituitary-testicular function of healthy men: a placebo-controlled double-blind trial. Acta Endocrinol (Copenh) 1989, 120:677-681.
127. Gupta AK, Lambert J, Revuz J, et al. Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur J Dermatol 2001, 11:6-10.
128. Castellsague J, Garcia-Rodriguez L-A, Duque A, et al. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatol 2002, 2:14.
129. Van Cauteren H, Heykants J, De Coster R, et al. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis 1987, 9(Suppl 1):S45-S46.
130. Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995, 172:599-602.
131. Stevens DA, Diaz M, Negroni R, et al. Safety evaluation of chronic fluconazole therapy. Chemotherapy 1997, 43:371-377.
132. Duswald KH, Penk A, Pittrow L High-dose therapy with fluconazole greater than or equal to 800 mg per day. Mycoses 1997, 40:267-277.
133. Dalle S, Skowron F, Ronger-Savie S, et al. Erythema multiforme induced by fluconazole. Dermatology 2005, 211:169.